Connect with us

Foreign

India’s drug controller grants approval of first intranasal COVID-19 vaccine

Published

on

Comptroller General of Drugs

– The Comptroller General of Drugs of India (DCGI) has granted approval for the first intranasal COVID-19 vaccine iNCOVACC, the Department of Biotechnology said on Tuesday.

jvzoo blogger outreach nigerian dailies today newspapers

Bharat Biotech International Limited (BBIL), the manufacturer of iNCOVACC (BBV154), has received emergency restricted use approval for persons aged 18 years and over in India for heterologous booster doses.

nigerian dailies today newspapers

The vaccine manufacturer said in a statement: “iNCOVACC is a recombinant replication-deficient adenovirus vectored vaccine with a stabilized SARS-CoV-2 spike protein prior to fusion. This vaccine candidate was evaluated in Phase I clinical trials.” , II and III with successful results.”

nigerian dailies today newspapers

“iNCOVACC has been specifically formulated to allow intranasal delivery via nasal drops. The nasal delivery system has been designed and developed to be cost-effective in low- and middle-income countries.”

According to Bharat Biotech, iNCOVACC was developed in partnership with Washington University in St. Louis, which had designed and developed the recombinant adenovirus-vectored construct and evaluated it in preclinical studies for efficacy. ■

(Xinhua)

https://nnn.ng/naira-black-market-exchange-rate-today/

hausa 24 link shortner twitter PuhuTV downloader

NNN is an online news portal that publishes breaking news in around the world. Contact: editor @ nnn.ng. Disclaimer.